Orgenesis Inc. Faces Delisting from Nasdaq, Director Resignation Prompted by Personal Reasons

On December 24, 2024, Orgenesis Inc. received notification from the Nasdaq Stock Market (“Nasdaq”) of its intent to file a notification of removal from listing (Form 25) with the Securities and Exchange Commission (SEC) to delist the company’s common stock on completion of all relevant procedures. The delisting, upon filing of the Form 25 by […]

Leave a Reply

Your email address will not be published.

Previous post Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com
Next post XTI Aerospace Reports Voting Results from 2024 Annual Meeting